Polycystic Ovary Syndrome

Data from a Johns Hopkins Medicine-led analysis provide insight into the risk of cardiovascular complications among women with polycystic ovary syndrome during delivery hospitalizations compared to their counterparts without PCOS.

Data presented at the European Congress of Endocrinology detail genetic and observational associations between obesity, and markers of body composition on the likelihood of developing PCOS later in life.

A systematic review and meta-analysis suggest approximately 20% of girls with type 2 diabetes also had polycystic ovary syndrome.

Results of a recent study shed light on observational and genetic associations between obesity and multiple female reproductive disorders, including uterine fibroids, PCOS, and heavy menstrual bleeding.

A pair of studies provide insight into the increased risk of dysglycemia among women with PCOS and the potential influence of combined oral contraceptive pills on this risk in a population-based cohort.

A meta-analysis builds upon previous research and provides new insight into the total costs of diagnosis and treating PCOS as well as the costs of treating PCOS-related comorbidities.

An overlooked aspect of an under-discussed condition, Andrea Dunaif, MD, provided an overview of the cardiovascular risk seen among women with polycystic ovary syndrome.

Data from a phase 2 study of women with overweight or obesity and polycystic ovary syndrome suggests use of licogliflozin was associated with significant reductions in hyperinsulinemia and androgenemia in this patient population.

A pilot trial in 29 women suggests a combination of metformin and high dose fish oil could reduce triglycerides and ApoB-remnants among young women with polycystic ovary syndrome.

A comparison of women with PCOS to matched controls indicates women with PCOS were at a 26% greater risk of experiencing major adverse cardiovascular events than their counterparts without polycystic ovary syndrome.

A meta-analysis of nearly a dozen studies presented at ENDO 2021 suggests Black women with PCOS were at an increased cardiometabolic risk, despite having comparable fasting glucose and lower triglyceride levels.

An analysis of 4k transgender youth and 16k propensity-matched controls is providing insight into the increased risk of conditions adversely impacting the cardiometabolic health of these patients.

This article features the top 5 stories in Endocrinology Network's coverage of women's health during 2020.

An analysis of data from more than 9 million women details the increased odds of developing gestational diabetes, gestational hypertension, and other complications associated with having polycystic ovary syndrome.

New research suggests children born to mothers with PCOS could be at an increased risk of developing a psychiatric disorder later in life.

An analysis of 41 individuals with premature adrenarche or polycystic ovary syndrome revealed more than half of the patients were glucocorticoid resistant.

A systematic review and meta-analysis are diving deeper into the debate over whether metformin should be prescribed to with polycystic ovary syndrome using assisted reproductive technologies, such as in vitro fertilization or intracytoplasmic sperm injection and embryo transfer.

An analysis of more than 60k women suggests those with polycystic ovary syndrome were 19% more likely to develop cardiovascular disease.

Leptin resistance may be responsible for elevated leptin levels in obese women with polycystic ovary syndrome, according to authors of this study. 

The GLP-1 receptor agonist/metformin combination did not support weight loss in this population but did increase pregnancy rates per in vitro embryo transfer.

Empagliflozin shown to significantly reduce liver fat in patients with T2DM, according to a new study.